Which description best describes 21 CFR Part 211?

Which description best describes 21 CFR Part 211?

• A. Good manufacturing practices for processing and manufacturing
• B. Good manufacturing practices for finished pharmaceuticals
• C. IRB
• D. Good clinical practice

Answer: (B)

The main idea here is that 21 CFR Part 211 specifies current good manufacturing practice requirements for finished pharmaceutical products. It sets the standards for how finished dosage forms—like tablets, capsules, and injectable drugs—are produced, tested, packaged, labeled, stored, and released to ensure consistent quality and safety. It covers aspects such as personnel, facilities, equipment, documentation, batch records, quality control, and stability, all focused on the finished product. This is distinct from general GMP for drug substances or manufacturing processes (which would relate to other parts), as well as from guidelines governing human research protections (IRB) or clinical trial conduct (GCP). So the description that best fits is good manufacturing practices for finished pharmaceuticals.

The main idea here is that 21 CFR Part 211 specifies current good manufacturing practice requirements for finished pharmaceutical products. It sets the standards for how finished dosage forms—like tablets, capsules, and injectable drugs—are produced, tested, packaged, labeled, stored, and released to ensure consistent quality and safety. It covers aspects such as personnel, facilities, equipment, documentation, batch records, quality control, and stability, all focused on the finished product.

This is distinct from general GMP for drug substances or manufacturing processes (which would relate to other parts), as well as from guidelines governing human research protections (IRB) or clinical trial conduct (GCP). So the description that best fits is good manufacturing practices for finished pharmaceuticals.